Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
- 1 March 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 381 (9869), 825-835
- https://doi.org/10.1016/s0140-6736(12)61961-8
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Molecular Targets in Meningococci: Efficient Routine Characterization and Optimal Outbreak Investigation in Conjunction with Routine Surveillance of the Meningococcal Group B Vaccine Candidate, fHBPClinical and Vaccine Immunology, 2011
- Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of LifeThe Pediatric Infectious Disease Journal, 2010
- Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccinesProceedings of the National Academy of Sciences of the United States of America, 2010
- Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humansProceedings of the National Academy of Sciences of the United States of America, 2010
- Increased Detection Rate of Kawasaki Disease Using New Diagnostic Algorithm, Including Early Use of EchocardiographyThe Journal of Pediatrics, 2009
- Investigation on the Effect of Immune Selection on Resistance to Bactericidal Antibodies to Group B Meningococci In VitroClinical and Vaccine Immunology, 2009
- Global epidemiology of meningococcal diseaseVaccine, 2009
- Meningococcal Factor H–Binding Protein Variants Expressed by Epidemic Capsular Group A, W‐135, and X Strains from AfricaThe Journal of Infectious Diseases, 2009
- Kawasaki Syndrome in DenmarkThe Pediatric Infectious Disease Journal, 2007
- A universal vaccine for serogroup B meningococcusProceedings of the National Academy of Sciences of the United States of America, 2006